JP5612239B2 - Ｈｔｌｖエンベロープのレセプターとしてのｇｌｕｔ１及びその使用 - Google Patents

Ｈｔｌｖエンベロープのレセプターとしてのｇｌｕｔ１及びその使用 Download PDF

Info

Publication number
JP5612239B2
JP5612239B2 JP2006505346A JP2006505346A JP5612239B2 JP 5612239 B2 JP5612239 B2 JP 5612239B2 JP 2006505346 A JP2006505346 A JP 2006505346A JP 2006505346 A JP2006505346 A JP 2006505346A JP 5612239 B2 JP5612239 B2 JP 5612239B2
Authority
JP
Japan
Prior art keywords
glut1
htlv
polypeptide
binding
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2006505346A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007535293A5 (enExample
JP2007535293A (ja
Inventor
ジャン−リュック ジョルジュ ローラン バッティーニ
ジャン−リュック ジョルジュ ローラン バッティーニ
ニコラ ガブリエル アルベール マネル
ニコラ ガブリエル アルベール マネル
フェリックス ジンヒュン キム
フェリックス ジンヒュン キム
サンドリナ キネ
サンドリナ キネ
ナオミ テイラー
ナオミ テイラー
マルク シットボン
マルク シットボン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Montpellier
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite de Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite de Montpellier filed Critical Centre National de la Recherche Scientifique CNRS
Publication of JP2007535293A publication Critical patent/JP2007535293A/ja
Publication of JP2007535293A5 publication Critical patent/JP2007535293A5/ja
Application granted granted Critical
Publication of JP5612239B2 publication Critical patent/JP5612239B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
JP2006505346A 2003-05-02 2004-04-30 Ｈｔｌｖエンベロープのレセプターとしてのｇｌｕｔ１及びその使用 Expired - Lifetime JP5612239B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03291067 2003-05-02
EP03291067.1 2003-05-02
PCT/EP2004/004624 WO2004096841A1 (en) 2003-05-02 2004-04-30 Glut-1 as a receptor for htlv envelopes and its uses

Publications (3)

Publication Number Publication Date
JP2007535293A JP2007535293A (ja) 2007-12-06
JP2007535293A5 JP2007535293A5 (enExample) 2012-01-26
JP5612239B2 true JP5612239B2 (ja) 2014-10-22

Family

ID=33396025

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006505346A Expired - Lifetime JP5612239B2 (ja) 2003-05-02 2004-04-30 Ｈｔｌｖエンベロープのレセプターとしてのｇｌｕｔ１及びその使用

Country Status (6)

Country Link
US (2) US7642061B2 (enExample)
EP (3) EP1648926B1 (enExample)
JP (1) JP5612239B2 (enExample)
DK (1) DK1648926T3 (enExample)
ES (1) ES2740827T3 (enExample)
WO (1) WO2004096841A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9777044B2 (en) * 2003-05-02 2017-10-03 Centre National De La Recherche Scientifique (Cnrs) GLUT-1 as a receptor for HTLV envelopes and its uses
WO2004096841A1 (en) * 2003-05-02 2004-11-11 Centre National De La Recherche Scientifique Glut-1 as a receptor for htlv envelopes and its uses
WO2007041268A2 (en) * 2005-09-30 2007-04-12 Xenoport, Inc. Transporter-targeted methods of diagnosis and treatment
US9791435B2 (en) * 2009-01-09 2017-10-17 Centre National De La Recherche Scientifique Receptor binding ligands, their use in the detection of cells with biological interest
US8870950B2 (en) 2009-12-08 2014-10-28 Mitral Tech Ltd. Rotation-based anchoring of an implant
WO2012035369A1 (en) 2010-09-17 2012-03-22 Centre National De La Recherche Scientifique Method for the diagnosis and/or prognosis of inflammatory states
AU2016229000B2 (en) * 2015-03-10 2021-11-04 The Trustees Of Columbia University In The City Of New York Recombinant Glut1 adeno-associated viral vector constructs and related methods for restoring Glut1 expression
WO2020070330A1 (en) 2018-10-05 2020-04-09 Metafora Biosystems Use of ligands derived from receptor-binding domain of porcine endogenous retrovirus type b for diagnosing smvt-related diseases
CN113527429B (zh) * 2020-04-15 2024-04-16 辽宁中健医药科技有限公司 人肝癌细胞特异结合多肽及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614366A (en) 1986-12-31 1997-03-25 Genelabs Technologies, Inc. HTLV-I peptide antigens and kit
AU1366088A (en) 1987-01-28 1988-08-24 Ortho Pharmaceutical Corporation Immunosuppressive peptides and methods of use
WO1996021727A1 (en) 1995-01-13 1996-07-18 Virogenetics Corporation Immunogenic compositions containing recombinant attenuated poxviruses expressing htlv antigens
US5698410A (en) 1995-06-07 1997-12-16 Mount Sinai School Of Medicine Of The City University Of New York Highly sensitive immunocytochemical method for diagnosis of malignant effusions
US5897991A (en) * 1995-06-07 1999-04-27 The Mount Sinai Medical Center Highly sensitive immunocytochemical method for diagnosis of malignant effusions
WO1997015668A2 (en) 1995-10-23 1997-05-01 Board Of Regents, The University Of Texas System Methods and compositions comprising glut-2 and glut-2 chimeras
EP0942748A4 (en) 1996-07-22 2004-12-08 Univ Rockefeller ENV-GLYCOPROTEIN VACCINE FOR PROTECTION AGAINST HTLV-I AND HTLV-II INFECTIONS
ATE365550T1 (de) 1998-03-13 2007-07-15 Univ Johns Hopkins Med Verwendung von einem protein kinase hemmer wie z.b. genistein bei der behandlung von diabetischer retinopathie
WO1999059559A1 (en) 1998-05-15 1999-11-25 Joslin Diabetes Center Independent regulation of basal and insulin-stimulated glucose transport
WO2004096841A1 (en) * 2003-05-02 2004-11-11 Centre National De La Recherche Scientifique Glut-1 as a receptor for htlv envelopes and its uses

Also Published As

Publication number Publication date
EP3168227A1 (en) 2017-05-17
EP3168227B1 (en) 2019-05-22
EP2610265A1 (en) 2013-07-03
WO2004096841A1 (en) 2004-11-11
US8945583B2 (en) 2015-02-03
WO2004096841A8 (en) 2006-01-19
ES2740827T3 (es) 2020-02-06
US20100056448A1 (en) 2010-03-04
DK1648926T3 (da) 2013-10-14
EP1648926A1 (en) 2006-04-26
EP2610265B1 (en) 2016-11-16
US7642061B2 (en) 2010-01-05
EP1648926B1 (en) 2013-07-03
JP2007535293A (ja) 2007-12-06
US20080268424A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
US8945583B2 (en) GLUT-1 as a receptor for HTLV envelopes and its uses
Manel et al. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV
McNatt et al. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants
Jones et al. Human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 use different receptor complexes to enter T cells
DK2376917T3 (en) New receptorbindingsligander, use thereof for the detection of cells of biological interest
Bouchet et al. Inhibition of the Nef regulatory protein of HIV-1 by a single-domain antibody
Dimitrov et al. A mechanism of resistance to HIV-1 entry: inefficient interactions of CXCR4 with CD4 and gp120 in macrophages
Sharma et al. Efficient infection of a human T-cell line and of human primary peripheral blood leukocytes with a pseudotyped retrovirus vector.
Blot et al. Human Dlg protein binds to the envelope glycoproteins of human T-cell leukemia virus type 1 and regulates envelope mediated cell-cell fusion in T lymphocytes
Jones et al. Induction of human T cell leukemia virus type I receptors on quiescent naive T lymphocytes by TGF-β
US20160090402A1 (en) Peptide domain required for interaction between the envelope of a virus pertaining to the herv-w interference group and an hasct receptor
JPH11510696A (ja) 物質をスクリーニングする方法におけるまたはそれに関する改良
US20180002383A1 (en) Glut-1 as a receptor for htlv envelopes and its uses
Lucas et al. Pseudotyping incompatibility between HIV-1 and gibbon ape leukemia virus Env is modulated by Vpu
US6054281A (en) Binding assays
US7803555B2 (en) Methods and compositions for use in the treatment of filovirus mediated disease conditions
Wang et al. GB virus type C E2 protein inhibits human immunodeficiency virus type 1 gag assembly by downregulating human ADP-ribosylation factor 1
AU2004278761A1 (en) HIV-dependent expression constructs and uses therefor
Murcia Late restriction induced by an endogenous retrovirus
WO2001041784A1 (en) Methods and compositions for use in the treatment of filovirus mediated disease conditions
Awasthi Role of the human T cell lymphotropic virus type-1 (HTLV-1) accessory protein p30 (II) in adult T cell leukemogenesis
Keir HIV-1 pathogenesis of the human thymus
Kucharzik et al. Lateral membrane lipoxin A4 receptors mediate LXA4's anti-inflammatory actions on intestinal epithelium
Huang et al. Induction of Human T Cell Leukemia Virus
Ramirez Mechanisms of immune evasion mediated by HIV-1 Vpu

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100623

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101020

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110726

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20111128

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120202

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120323

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130605

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140715

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140904

R150 Certificate of patent or registration of utility model

Ref document number: 5612239

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term